{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T07:53:38Z","timestamp":1648886018722},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T00:00:00Z","timestamp":1462233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2315-0","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T12:16:01Z","timestamp":1462277761000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark"],"prefix":"10.1186","volume":"16","author":[{"given":"Haojie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinna P.","family":"Ulrichsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra K.","family":"Thygesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanenne J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"key":"2315_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clindermatol.2008.09.001","volume":"27","author":"C Garbe","year":"2009","unstructured":"Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3\u20139.","journal-title":"Clin Dermatol"},{"key":"2315_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","volume":"16","author":"C Garbe","year":"2011","unstructured":"Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5\u201324.","journal-title":"Oncologist"},{"key":"2315_CR3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med"},{"key":"2315_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107\u201314.","journal-title":"N Engl J Med"},{"key":"2315_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet"},{"key":"2315_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"2315_CR7","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","volume":"24","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24:2174\u201380.","journal-title":"Ann Oncol"},{"key":"2315_CR8","unstructured":"ZELBORAF Prescribing Information (USPI, United States Product Insert), in, 2011"},{"key":"2315_CR9","unstructured":"TAFINLAR Prescribing Information (USPI, United States Product Insert), in, 2014"},{"key":"2315_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","volume":"167","author":"RM Anforth","year":"2012","unstructured":"Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167:1153\u201360.","journal-title":"Br J Dermatol"},{"key":"2315_CR11","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/jco.2010.28.15_suppl.8503","volume":"28","author":"R Kefford","year":"2010","unstructured":"Kefford R, Arkenau H, Brown MP, et al. Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol. 2010;28:8503. abstr.","journal-title":"J Clin Oncol"},{"key":"2315_CR12","doi-asserted-by":"crossref","unstructured":"Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2011;29:8509.","DOI":"10.1200\/jco.2011.29.15_suppl.8509"},{"key":"2315_CR13","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/sj.jid.5700375","volume":"126","author":"OP Clausen","year":"2006","unstructured":"Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol. 2006;126:2308\u201315.","journal-title":"J Invest Dermatol"},{"key":"2315_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1067\/mjd.2000.103339","volume":"42","author":"RG Glogau","year":"2000","unstructured":"Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"2315_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1365-4362.1992.tb04240.x","volume":"31","author":"E Ledo","year":"1992","unstructured":"Ledo E. Wart, keratoacanthoma, and squamous cell carcinoma: a spectrum of the same neoplastic process? Int J Dermatol. 1992;31:777\u20138.","journal-title":"Int J Dermatol"},{"key":"2315_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000018276","volume":"199","author":"B Cribier","year":"1999","unstructured":"Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology. 1999;199:208\u201312.","journal-title":"Dermatology"},{"key":"2315_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00000372-199308000-00007","volume":"15","author":"E Hodak","year":"1993","unstructured":"Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15:332\u201342.","journal-title":"Am J Dermatopathol"},{"key":"2315_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2310\/7750.2008.07042","volume":"12","author":"RF Magalhaes","year":"2008","unstructured":"Magalhaes RF, Cruvinel GT, Cintra GF, et al. Diagnosis and follow-up of keratoacanthoma-like lesions: clinical-histologic study of 43 cases. J Cutan Med Surg. 2008;12:163\u201373.","journal-title":"J Cutan Med Surg"},{"key":"2315_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1365-2133.1994.tb08580.x","volume":"131","author":"A Patel","year":"1994","unstructured":"Patel A, Halliday GM, Cooke BE, et al. Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma. Br J Dermatol. 1994;131:789\u201398.","journal-title":"Br J Dermatol"},{"key":"2315_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0190-9622(84)80010-9","volume":"10","author":"MA Goldenhersh","year":"1984","unstructured":"Goldenhersh MA, Olsen TG. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma. J Am Acad Dermatol. 1984;10:372\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"2315_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1403494810393562","volume":"39","author":"ML Gjerstorff","year":"2011","unstructured":"Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39:42\u20135.","journal-title":"Scand J Public Health"},{"key":"2315_CR22","first-page":"535","volume":"44","author":"HH Storm","year":"1997","unstructured":"Storm HH, Michelsen EV, Clemmensen IH, et al. The Danish Cancer Registry--history, content, quality and use. Dan Med Bull. 1997;44:535\u20139.","journal-title":"Dan Med Bull"},{"key":"2315_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CLEP.S9908","volume":"2","author":"R Erichsen","year":"2010","unstructured":"Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51\u20136.","journal-title":"Clin Epidemiol"},{"key":"2315_CR24","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","volume":"287","author":"L Frank","year":"2000","unstructured":"Frank L, Epidemiology. When an entire country is a cohort. Science. 2000;287:2398\u20139.","journal-title":"Science"},{"key":"2315_CR25","doi-asserted-by":"crossref","unstructured":"Schmidt M, Pedersen L, Sorensen HT. The danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549.","DOI":"10.1007\/s10654-014-9930-3"},{"key":"2315_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.7326\/0003-4819-105-3-429","volume":"105","author":"R Simon","year":"1986","unstructured":"Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med. 1986;105:429\u201335.","journal-title":"Ann Intern Med"},{"key":"2315_CR27","unstructured":"Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL, editors. Comparability and quality control in cancer registration. (IARC Technical Report No. 19). Lyon: IARC (WHO) and IACR; 1994"},{"key":"2315_CR28","unstructured":"Sorensen HT, Christensen T, Schlosser HK, et al. Use of medical databases in clinical epidemiology. Department of Clinical Epidemiology, Aarhus, Denmark: SUN-TRYK, Aarhus University; 2009"},{"key":"2315_CR29","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.25411","volume":"127","author":"F Birch-Johansen","year":"2010","unstructured":"Birch-Johansen F, Jensen A, Mortensen L, et al. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978\u20132007: Rapid incidence increase among young Danish women. Int J Cancer. 2010;127:2190\u20138.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2315-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2315-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2315-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2315-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T03:11:50Z","timestamp":1506136310000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2315-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2315-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,3]]},"article-number":"295"}}